Sunesis Pharmaceuticals (FRA:RYIS) Momentum Rank : 0 (As of May. 25, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Momentum Rank?

Sunesis Pharmaceuticals has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Sunesis Pharmaceuticals Momentum Rank Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines